{
    "eid": "2-s2.0-85043683102",
    "title": "Cinacalcet for treatment of chronic kidney disease-mineral and bone disorder: A meta-analysis of randomized controlled trials",
    "cover-date": "2018-06-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Physiology",
            "@code": "1314",
            "@abbrev": "BIOC"
        },
        {
            "@_fa": "true",
            "$": "Nephrology",
            "@code": "2727",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Urology",
            "@code": "2748",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Physiology (medical)",
            "@code": "2737",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Chronic kidney disease-mineral bone disorders",
        "Cinacalcet",
        "Meta-analysis"
    ],
    "authors": [
        "Primploy Greeviroj",
        "Thidarat Kitrungphaiboon",
        "Pisut Katavetin",
        "Kearkiat Praditpornsilpa",
        "Somchai Eiam-Ong",
        "Bertrand L. Jaber",
        "Paweena Susantitaphong"
    ],
    "citedby-count": 16,
    "ref-count": 45,
    "ref-list": [
        "The burden of chronic kidney disease on developing nations: A 21st century challenge in global health",
        "KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)",
        "K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease",
        "FGF23 induces left ventricular hypertrophy",
        "Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease",
        "Time-averaged level of fibroblast growth factor-23 and clinical events in chronic kidney disease",
        "Sensipar (cinacalcet) Tablets",
        "Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl",
        "The OPTIMA study: Assessing a new cinacalcet (Sensipar/ Mimpara) treatment algorithm for secondary hyperparathyroidism",
        "Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients",
        "Meta-analysis of biochemical and patient-level effects of calcimimetic therapy",
        "Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: A meta-analysis",
        "The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: A meta-analysis",
        "Cinacalcet in patients with chronic Kidney disease: A cumulative meta-analysis of randomized controlled trials",
        "Cinacalcet versus standard treatment for chronic kidney disease: A systematic review and metaanalysis",
        "Assessing heterogeneity in meta-analysis: Q statistic or I2 index?",
        "Bias in meta-analysis detected by a simple, graphical test",
        "A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism",
        "The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism",
        "The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism",
        "The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease",
        "Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis",
        "Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily",
        "Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study",
        "Firstand second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl",
        "Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients",
        "Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism",
        "Cinacalcet HCl and concurrent low-dose Vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with Vitamin D alone: The ACHIEVE study results",
        "Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism",
        "An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism",
        "The ADVANCE study: A randomized study to evaluate the effects of cinacalcet plus low-dose Vitamin D on vascular calcification in patients on hemodialysis",
        "Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis",
        "Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active Vitamin D in peritoneal dialysis patients: A randomized controlled study",
        "Calciummediated parathyroid hormone suppression to assess progression of secondary hyperparathyroidism during treatment among incident dialysis patients",
        "Efficacy of cinacalcet with low-dose Vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism",
        "Paricalcitol versus cinacalcet plus low-dose Vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: Results of the IMPACT SHPT study",
        "Effect of cinacalcet and Vitamin D analogs on fibroblast growth factor-23 during the treatment of secondary hyperparathyroidism",
        "Efficacy and safety of Cinacalcet on secondary hyperparathyroidism in Chinese chronic kidney disease patients receiving hemodialysis",
        "Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study",
        "Recent advances in the noninvasive diagnosis of renal osteodystrophy",
        "Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients-a single-center cohort study",
        "Low bone mineral density and fractures in stages 3-5 CKD: An updated systematic review and meta-analysis",
        "Effects of cinacalcet on fracture events in patients receiving hemodialysis: The EVOLVE trial",
        "Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: The evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Boston",
            "@id": "60018759",
            "affilname": "Caritas St. Elizabeth's Medical Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60018759",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Boston",
            "@id": "60015849",
            "affilname": "Tufts University School of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015849",
            "affiliation-country": "United States"
        }
    ],
    "funding": [
        "Thailand research fund #RSA"
    ]
}